James Noble
2016
In 2016, James Noble earned a total compensation of $1.9M as Chief Executive Officer at Adaptimmune Therapeutics, a 152% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $97,099 |
|---|---|
| Option Awards | $1,411,405 |
| Salary | $388,395 |
| Other | $20,465 |
| Total | $1,917,364 |
Noble received $1.4M in option awards, accounting for 74% of the total pay in 2016.
Noble also received $97.1K in non-equity incentive plan, $388.4K in salary and $20.5K in other compensation.
Rankings
In 2016, James Noble's compensation ranked 5,075th out of 14,075 executives tracked by ExecPay. In other words, Noble earned more than 63.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,075 out of 14,075 | 64th |
Division Manufacturing | 1,810 out of 5,489 | 67th |
Major group Chemicals And Allied Products | 574 out of 1,895 | 70th |
Industry group Drugs | 430 out of 1,538 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 73 out of 279 | 74th |
Source: SEC filing on April 28, 2017.
Noble's colleagues
We found three more compensation records of executives who worked with James Noble at Adaptimmune Therapeutics in 2016.